Ezetimibe/Rosuvastatin Calcium/Cilostazol

依折麦布/瑞舒伐他汀钙/西洛他唑

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEzetimibe/Rosuvastatin Calcium/Cilostazol
Drug Alias Name依折麦布+瑞舒伐他汀钙+西洛他唑Ezetimibe+Rosuvastatin Calcium+CilostazolHCP-1703
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsNiemann-Pick C1-like protein 1 inhibitorsPhosphodiesterase 3 inhibitors +[4] 
TargetsPhosphodiesterase 3HMG-CoA reductaseNiemann-Pick C1-like protein 1
Therapy Area/IndicationsHyperlipidemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes CilostazolEzetimibeRosuvastatin Calcium
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHyperlipidemias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A